LC
CATX icon

Lindbrook Capital’s Perspective Therapeutics CATX Stock Holding History

Lindbrook Capital’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-31
Closed -$414 – 2797
2024
Q3 		$414 Buy
+31
New +$412 ﹤0.01% 2713

Other funds holding CATX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NWMG
Nicholson Wealth Management Group Charlestown, South Carolina $170M AUM 10.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Lindbrook Capital's CATX Position: Q4 2024 in Review

Lindbrook Capital sold out of Perspective Therapeutics (CATX) in Q4 2024, closing a stake of 31 shares — an estimated $414 sold.

Lindbrook Capital first reported a position in CATX in Q3 2024 and held it in 1 quarter. The position peaked at $414 in Q3 2024. 135 funds tracked by Wall St. Rank hold CATX as of Q4 2024.

  • Lindbrook Capital reported no remaining Perspective Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Lindbrook Capital sold 31 Perspective Therapeutics shares in Q4 2024, an estimated $414.
  • Lindbrook Capital first reported a position in Perspective Therapeutics in Q3 2024 and held it in 1 quarter.
  • Lindbrook Capital's Perspective Therapeutics position peaked at $414 in Q3 2024.
  • 135 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q4 2024.

Based on Lindbrook Capital's 13F filing for Q4 2024, filed 6 Feb 2025.